Which has higher earnings and valuation, BDSX or DCGO?

Biodesix has higher earnings, but lower revenue than DocGo. Biodesix is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodesix $96.10M 2.38 -$35.26M -$4.06 N/A DocGo $322.20M 0.19 -$182.40M -$1.91 N/A

Is BDSX or DCGO more profitable?

Biodesix has a net margin of -33.26% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Biodesix -33.26% -2,101.40% -35.65% DocGo -62.23% -44.09% -29.14%

Does the media prefer BDSX or DCGO?

In the previous week, Biodesix had 2 more articles in the media than DocGo. MarketBeat recorded 4 mentions for Biodesix and 2 mentions for DocGo. DocGo's average media sentiment score of 0.94 beat Biodesix's score of 0.92 indicating that DocGo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodesix 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DocGo 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, DCGO or LFMD?

LifeMD has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.19 -$182.40M -$1.91 N/A LifeMD $193.33M 0.94 $14.35M $0.05 74.90

Is DCGO or LFMD more profitable?

LifeMD has a net margin of 2.37% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -62.23% -44.09% -29.14% LifeMD 2.37% -150.88% -22.59%

Does the media refer more to DCGO or LFMD?

In the previous week, DocGo and DocGo both had 2 articles in the media. LifeMD's average media sentiment score of 0.97 beat DocGo's score of 0.94 indicating that LifeMD is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DocGo 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LifeMD 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, XGN or DCGO?

Exagen has higher earnings, but lower revenue than DocGo. Exagen is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $68.38M 1.45 -$19.95M -$0.89 N/A DocGo $322.20M 0.19 -$182.40M -$1.91 N/A

Is XGN or DCGO more profitable?

Exagen has a net margin of -29.49% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -29.49% -94.37% -28.96% DocGo -62.23% -44.09% -29.14%

Does the media prefer XGN or DCGO?

In the previous week, Exagen had 2 more articles in the media than DocGo. MarketBeat recorded 4 mentions for Exagen and 2 mentions for DocGo. DocGo's average media sentiment score of 0.94 beat Exagen's score of 0.63 indicating that DocGo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DocGo 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BNR or DCGO?

DocGo has a consensus price target of $2.38, indicating a potential upside of 279.39%. Given DocGo's stronger consensus rating and higher probable upside, analysts clearly believe DocGo is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 DocGo 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better valuation and earnings, BNR or DCGO?

Burning Rock Biotech has higher revenue and earnings than DocGo. Burning Rock Biotech is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Burning Rock Biotech $514.43M 0.19 -$7.92M -$0.82 N/A DocGo $322.20M 0.19 -$182.40M -$1.91 N/A

Does the media prefer BNR or DCGO?

In the previous week, Burning Rock Biotech and Burning Rock Biotech both had 2 articles in the media. Burning Rock Biotech's average media sentiment score of 1.68 beat DocGo's score of 0.94 indicating that Burning Rock Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Burning Rock Biotech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive DocGo 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PARK or DCGO?

In the previous week, Park Dental Partners had 1 more articles in the media than DocGo. MarketBeat recorded 3 mentions for Park Dental Partners and 2 mentions for DocGo. DocGo's average media sentiment score of 0.94 beat Park Dental Partners' score of 0.32 indicating that DocGo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Park Dental Partners 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral DocGo 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

DocGo (DCGO) Competitors

$0.63 0.00 (-0.62%)

As of 09:44 AM Eastern

Compare

DCGO vs. BDSX, LFMD, XGN, BNR, and PARK

Should you buy DocGo stock or one of its competitors? MarketBeat compares DocGo with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DocGo include Biodesix (BDSX), LifeMD (LFMD), Exagen (XGN), Burning Rock Biotech (BNR), and Park Dental Partners (PARK). These companies are all part of the "healthcare" industry.

How does DocGo compare to Biodesix?

Biodesix (NASDAQ:BDSX) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

Biodesix currently has a consensus target price of $28.33, suggesting a potential upside of 28.07%. DocGo has a consensus target price of $2.38, suggesting a potential upside of 279.39%. Given DocGo's higher probable upside, analysts clearly believe DocGo is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Biodesix had 2 more articles in the media than DocGo. MarketBeat recorded 4 mentions for Biodesix and 2 mentions for DocGo. DocGo's average media sentiment score of 0.94 beat Biodesix's score of 0.92 indicating that DocGo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biodesix has higher earnings, but lower revenue than DocGo. Biodesix is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$96.10M	2.38	-$35.26M	-$4.06	N/A
DocGo	$322.20M	0.19	-$182.40M	-$1.91	N/A

Biodesix has a net margin of -33.26% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-33.26%	-2,101.40%	-35.65%
DocGo	-62.23%	-44.09%	-29.14%

21.0% of Biodesix shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 23.2% of Biodesix shares are owned by company insiders. Comparatively, 5.1% of DocGo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Biodesix has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, DocGo has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market.

Summary

DocGo beats Biodesix on 9 of the 16 factors compared between the two stocks.

How does DocGo compare to LifeMD?

DocGo (NASDAQ:DCGO) and LifeMD (NASDAQ:LFMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

56.4% of DocGo shares are owned by institutional investors. Comparatively, 35.5% of LifeMD shares are owned by institutional investors. 5.1% of DocGo shares are owned by insiders. Comparatively, 17.2% of LifeMD shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

LifeMD has a net margin of 2.37% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
LifeMD	2.37%	-150.88%	-22.59%

DocGo has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market. Comparatively, LifeMD has a beta of 1.99, suggesting that its share price is 99% more volatile than the broader market.

DocGo currently has a consensus target price of $2.38, indicating a potential upside of 279.39%. LifeMD has a consensus target price of $9.14, indicating a potential upside of 144.14%. Given DocGo's higher possible upside, analysts plainly believe DocGo is more favorable than LifeMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
LifeMD	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

LifeMD has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.19	-$182.40M	-$1.91	N/A
LifeMD	$193.33M	0.94	$14.35M	$0.05	74.90

In the previous week, DocGo and DocGo both had 2 articles in the media. LifeMD's average media sentiment score of 0.97 beat DocGo's score of 0.94 indicating that LifeMD is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LifeMD	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

LifeMD beats DocGo on 11 of the 15 factors compared between the two stocks.

How does DocGo compare to Exagen?

Exagen (NASDAQ:XGN) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Exagen has a beta of 2.02, meaning that its stock price is 102% more volatile than the broader market. Comparatively, DocGo has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market.

75.3% of Exagen shares are held by institutional investors. Comparatively, 56.4% of DocGo shares are held by institutional investors. 10.4% of Exagen shares are held by company insiders. Comparatively, 5.1% of DocGo shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Exagen had 2 more articles in the media than DocGo. MarketBeat recorded 4 mentions for Exagen and 2 mentions for DocGo. DocGo's average media sentiment score of 0.94 beat Exagen's score of 0.63 indicating that DocGo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exagen has a net margin of -29.49% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
DocGo	-62.23%	-44.09%	-29.14%

Exagen currently has a consensus target price of $9.11, suggesting a potential upside of 121.90%. DocGo has a consensus target price of $2.38, suggesting a potential upside of 279.39%. Given DocGo's higher possible upside, analysts plainly believe DocGo is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Exagen has higher earnings, but lower revenue than DocGo. Exagen is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$68.38M	1.45	-$19.95M	-$0.89	N/A
DocGo	$322.20M	0.19	-$182.40M	-$1.91	N/A

Summary

Exagen beats DocGo on 12 of the 17 factors compared between the two stocks.

How does DocGo compare to Burning Rock Biotech?

Burning Rock Biotech (NASDAQ:BNR) and DocGo (NASDAQ:DCGO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

30.0% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 56.4% of DocGo shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by insiders. Comparatively, 5.1% of DocGo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Burning Rock Biotech has a net margin of -11.57% compared to DocGo's net margin of -62.23%. Burning Rock Biotech's return on equity of -10.98% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
DocGo	-62.23%	-44.09%	-29.14%

DocGo has a consensus price target of $2.38, indicating a potential upside of 279.39%. Given DocGo's stronger consensus rating and higher probable upside, analysts clearly believe DocGo is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Burning Rock Biotech has higher revenue and earnings than DocGo. Burning Rock Biotech is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$514.43M	0.19	-$7.92M	-$0.82	N/A
DocGo	$322.20M	0.19	-$182.40M	-$1.91	N/A

Burning Rock Biotech has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, DocGo has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market.

In the previous week, Burning Rock Biotech and Burning Rock Biotech both had 2 articles in the media. Burning Rock Biotech's average media sentiment score of 1.68 beat DocGo's score of 0.94 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Burning Rock Biotech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Burning Rock Biotech beats DocGo on 9 of the 15 factors compared between the two stocks.

How does DocGo compare to Park Dental Partners?

Park Dental Partners (NASDAQ:PARK) and DocGo (NASDAQ:DCGO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

56.4% of DocGo shares are held by institutional investors. 10.6% of Park Dental Partners shares are held by insiders. Comparatively, 5.1% of DocGo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Park Dental Partners had 1 more articles in the media than DocGo. MarketBeat recorded 3 mentions for Park Dental Partners and 2 mentions for DocGo. DocGo's average media sentiment score of 0.94 beat Park Dental Partners' score of 0.32 indicating that DocGo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Park Dental Partners	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Park Dental Partners currently has a consensus price target of $21.75, suggesting a potential upside of 12.69%. DocGo has a consensus price target of $2.38, suggesting a potential upside of 279.39%. Given DocGo's higher possible upside, analysts clearly believe DocGo is more favorable than Park Dental Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Park Dental Partners has higher earnings, but lower revenue than DocGo. DocGo is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Park Dental Partners	$244.49M	0.36	-$360K	$0.74	26.08
DocGo	$322.20M	0.19	-$182.40M	-$1.91	N/A

Park Dental Partners has a net margin of 0.00% compared to DocGo's net margin of -62.23%. Park Dental Partners' return on equity of 0.00% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Park Dental Partners	N/A	N/A	N/A
DocGo	-62.23%	-44.09%	-29.14%

Summary

Park Dental Partners beats DocGo on 11 of the 16 factors compared between the two stocks.

Get DocGo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCGO vs. The Competition

Export

Metric	DocGo	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$63.69M	$9.50B	$6.90B	$12.16B
Dividend Yield	N/A	1.63%	2.67%	9.43%
P/E Ratio	-0.34	25.70	27.04	23.74
Price / Sales	0.19	18.98	494.06	76.07
Price / Cash	10.77	14.69	26.39	46.67
Price / Book	0.49	6.05	10.48	6.16
Net Income	-$182.40M	$179.69M	$3.60B	$331.26M
7 Day Performance	-2.60%	-2.03%	-1.67%	-0.72%
1 Month Performance	27.24%	-1.06%	-2.60%	-2.52%
1 Year Performance	-57.99%	10.73%	18.61%	14.76%

DocGo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCGO DocGo	3.3864 of 5 stars	$0.63 -0.6%	$2.38 +279.4%	-56.9%	$63.69M	$322.20M	N/A	3,568	Gap Up
BDSX Biodesix	3.4962 of 5 stars	$20.19 +1.2%	$28.33 +40.3%	+149.0%	$209.17M	$88.50M	N/A	220	Positive News
LFMD LifeMD	2.973 of 5 stars	$4.15 -7.8%	$9.14 +120.3%	-63.8%	$200.69M	$194.05M	83.02	230
XGN Exagen	2.9959 of 5 stars	$4.39 +3.3%	$9.11 +107.5%	-39.5%	$106.06M	$66.57M	N/A	220	News Coverage Upcoming Earnings
BNR Burning Rock Biotech	1.3989 of 5 stars	$9.97 +3.9%	N/A	+37.9%	$104.88M	$77.16M	N/A	1,390	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCGO) was last updated on 7/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DocGo (DCGO) Competitors